Role of the gap junctions in the contractile response to agonists in pulmonary artery from two rat models of pulmonary hypertension

Respiratory Research

Christelle Guibert²  Jean-Pierre Savineau²  Roger Marthan¹  Diana Dahan²  Marie Billaud² 

[1] CHU de Bordeaux, F 33076 Bordeaux, France;Université Bordeaux Segalen, Centre de Recherche Cardio-Thoracique de Bordeaux, F-33076 Bordeaux, France

关键词: connexin-mimetic peptides;    monocrotaline;    chronic hypoxia;    vasoreactivity;    connexin;    gap junctions;    pulmonary hypertension;   

Others  :  796896
DOI  :  10.1186/1465-9921-12-30

 received in 2010-10-19, accepted in 2011-03-17,  发布年份 2011

【 授权许可】

   
2011 Billaud et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Goodenough DA, Paul DL: Gap junctions. Cold Spring Harbor Perspect Biol 2009, 1:a002576.
• [2]Cottrell GT, Burt JM: Functional consequences of heterogeneous gap junction channel formation and its influence in health and disease. Biochim Biophys Acta 2005, 1711:126-141.
• [3]Brisset AC, Isakson BE, Kwak BR: Connexins in vascular physiology and pathology. Antioxid Redox Signal 2009, 11:267-282.
• [4]Rummery NM, Hill CE: Vascular gap junctions and implications for hypertension. Clin Exp Pharmacol Physiol 2004, 31:659-667.
• [5]Cowan DB, Jones M, Garcia LM, Noria S, del Nido PJ, McGowan FX Jr: Hypoxia and stretch regulate intercellular communication in vascular smooth muscle cells through reactive oxygen species formation. Arterioscler Thromb Vasc Biol 2003, 23:1754-1760.
• [6]Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
• [7]Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-54.
• [8]Humbert M: Update in pulmonary hypertension 2008. Am J Respir Crit Care Med 2009, 179:650-656.
• [9]Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
• [10]Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995, 99:249-254.
• [11]Hosoda Y: Pathology of pulmonary hypertension: a human and experimental study. Pathol Int 1994, 44:241-267.
• [12]Kanai Y, Hori S, Tanaka T, Yasuoka M, Watanabe K, Aikawa N, Hosoda Y: Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 1993, 27:1619-1623.
• [13]Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993, 73:887-897.
• [14]Salvi SS: Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest 1999, 115:1708-1719.
• [15]Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:13S-24S.
• [16]Shimoda LA, Sham JS, Sylvester JT: Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res 2000, 49:549-560.
• [17]Guibert C, Marthan R, Savineau JP: Modulation of ion channels in pulmonary arterial hypertension. Curr Pharm Des 2007, 13:2443-2455.
• [18]Billaud M, Marthan R, Savineau JP, Guibert C: Vascular smooth muscle modulates endothelial control of vasoreactivity via reactive oxygen species production through myoendothelial communications. PLoS One 2009, 4:e6432.
• [19]Chaytor AT, Evans WH, Griffith TM: Peptides homologous to extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries. J Physiol 1997, 503(Pt 1):99-110.
• [20]Tual-Chalot S, Guibert C, Muller B, Savineau JP, Andriantsitohaina R, Martinez MC: Circulating Microparticles from Pulmonary Hypertensive Rats Induce Endothelial Dysfunction. Am J Respir Crit Care Med 2010, 182:261-268.
• [21]Rodat-Despoix L, Crevel H, Marthan R, Savineau JP, Guibert C: Heterogeneity in 5-HT-induced contractile and proliferative responses in rat pulmonary arterial bed. J Vasc Res 2008, 45:181-192.
• [22]Rodat L, Savineau JP, Marthan R, Guibert C: Effect of chronic hypoxia on voltage-independent calcium influx activated by 5-HT in rat intrapulmonary arteries. Pflugers Arch 2007, 454:41-51.
• [23]Guibert C, Savineau JP, Crevel H, Marthan R, Rousseau E: Effect of short-term organoid culture on the pharmaco-mechanical properties of rat extra- and intrapulmonary arteries. Br J Pharmacol 2005, 146:692-701.
• [24]Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR: Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001, 89:1231-1239.
• [25]MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I: 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996, 119:917-930.
• [26]Sauvageau S, Thorin E, Villeneuve L, Dupuis J: Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels. Pulm Pharmacol Ther 2009, 22:311-317.
• [27]MacLean MR, McCulloch KM, Baird M: Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 1994, 23:838-845.
• [28]Mam V, Tanbe AF, Vitali SH, Arons E, Christou HA, Khalil RA: Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 2010, 332:455-462.
• [29]Bonnet S, Dubuis E, Vandier C, Martin S, Marthan R, Savineau JP: Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing. Cardiovasc Res 2002, 53:1019-1028.
• [30]Hyvelin JM, Guibert C, Marthan R, Savineau JP: Cellular mechanisms and role of endothelin-1-induced calcium oscillations in pulmonary arterial myocytes. Am J Physiol 1998, 275:L269-282.
• [31]Ivy D, McMurtry IF, Yanagisawa M, Gariepy CE, Le Cras TD, Gebb SA, Morris KG, Wiseman RC, Abman SH: Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1040-1048.
• [32]Guibert C, Marthan R, Savineau JP: 5-HT induces an arachidonic acid-sensitive calcium influx in rat small intrapulmonary artery. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1228-1236.
• [33]McDaniel SS, Platoshyn O, Wang J, Yu Y, Sweeney M, Krick S, Rubin LJ, Yuan JX: Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001, 280:L870-880.
• [34]Shimoda LA, Sylvester JT, Sham JS: Mobilization of intracellular Ca(2+) by endothelin-1 in rat intrapulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000, 278:L157-164.
• [35]Barman SA: Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am J Physiol Lung Cell Mol Physiol 2007, 293:L472-479.
• [36]Rodat-Despoix L, Aires V, Ducret T, Marthan R, Savineau JP, Rousseau E, Guibert C: Signalling pathways involved in the contractile response to 5-HT in human pulmonary artery. Eur Respir J 2009, 34:1338-1347.
• [37]Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G: Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000, 275:21722-21729.
• [38]de Wit C, Griffith TM: Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses. Pflugers Arch 2010, 459:897-914.